Global Remicade Biosimilar Market Growth, Share, Size, Trends and Forecast (2024 - 2030)

By Disease Indication;

Crohn’s disease, Rheumatoid arthritis, Ankylosing spondylitis, Psoriatic arthritis, Ulcerative Colitis and Plaque psoriasis.

By Geography;

North America, Europe, Asia Pacific, Middle East and Africa and Latin America - Report Timeline (2020 - 2030).
Report ID: Rn098461069 Published Date: October, 2024 Updated Date: November, 2024

Introduction

Global Remicade Biosimilar Market (USD Million), 2020 - 2030

In the year 2023, the Global Remicade Biosimilar Market was valued at USD 3,023.16 million. The size of this market is expected to increase to USD 26,854.51 million by the year 2030, while growing at a Compounded Annual Growth Rate (CAGR) of 36.6%.

The global Remicade biosimilar market has experienced significant growth in recent years, driven by the rising prevalence of chronic diseases such as rheumatoid arthritis, Crohn's disease, and ulcerative colitis. Biosimilars are biologic medical products highly similar to already approved reference products, in this case, Remicade (infliximab), which has been widely used for treating autoimmune disorders. The market's expansion is further fueled by the increasing demand for cost-effective treatments as biosimilars offer a more affordable alternative to expensive biologic therapies without compromising efficacy and safety.

Europe and North America are currently the dominant regions in the Remicade biosimilar market, largely due to favorable regulatory environments and the high adoption rate of biosimilars. In Europe, the European Medicines Agency (EMA) has been instrumental in the approval and uptake of biosimilars, while in the United States, the FDA's Biologics Price Competition and Innovation Act has paved the way for biosimilar approvals. Emerging markets in Asia-Pacific and Latin America are also showing substantial growth potential, driven by increasing healthcare access, rising healthcare expenditures, and supportive government policies aimed at reducing healthcare costs.

Key players in the Remicade biosimilar market include Pfizer Inc., Celltrion Healthcare, Samsung Bioepis, and Amgen Inc. These companies are investing heavily in research and development to enhance their biosimilar portfolios and gain a competitive edge. Additionally, strategic collaborations, partnerships, and acquisitions are common strategies adopted by these firms to strengthen their market position and expand their global reach. As the market continues to evolve, ongoing advancements in biotechnology and regulatory frameworks are expected to further drive the adoption and acceptance of Remicade biosimilars worldwide.

  1. Introduction
    1. Research Objectives and Assumptions
    2. Research Methodology
    3. Abbreviations
  2. Market Definition & Study Scope
  3. Executive Summary
    1. Market Snapshot, By Disease Indication
    2. Market Snapshot, By Region
  4. Global Remicade Biosimilar Market Dynamics
    1. Drivers, Restraints and Opportunities
      1. Drivers
        1. Rising Prevalence of Chronic Diseases
        2. Increasing Demand for Cost-Effective Treatments
        3. Favorable Regulatory Environments
      2. Restraints
        1. High Development Costs
        2. Regulatory and Approval Challenges
        3. Physician and Patient Reluctance
      3. Opportunities
        1. Expansion in Emerging Markets
        2. Advances in Biotechnology
        3. Strategic Collaborations and Partnerships
    2. PEST Analysis
      1. Political Analysis
      2. Economic Analysis
      3. Social Analysis
      4. Technological Analysis
    3. Porter's Analysis
      1. Bargaining Power of Suppliers
      2. Bargaining Power of Buyers
      3. Threat of Substitutes
      4. Threat of New Entrants
      5. Competitive Rivalry
  5. Market Segmentation
    1. Global Remicade Biosimilar Market, By Disease Indication, 2020 - 2030 (USD Million)
      1. Crohn’s disease
      2. Rheumatoid arthritis
      3. Ankylosing spondylitis
      4. Psoriatic arthritis
      5. Ulcerative Colitis
      6. Plaque psoriasis
    2. Global Remicade Biosimilar Market, By Geography, 2020 - 2030 (USD Million)
      1. North America
        1. United States
        2. Canada
      2. Europe
        1. Germany
        2. United Kingdom
        3. France
        4. Italy
        5. Spain
        6. Nordic
        7. Benelux
        8. Rest of Europe
      3. Asia Pacific
        1. Japan
        2. China
        3. India
        4. Australia & New Zealand
        5. South Korea
        6. ASEAN (Association of South East Asian Countries)
        7. Rest of Asia Pacific
      4. Middle East & Africa
        1. GCC
        2. Israel
        3. South Africa
        4. Rest of Middle East & Africa
      5. Latin America
        1. Brazil
        2. Mexico
        3. Argentina
        4. Rest of Latin America
  6. Competitive Landscape
    1. Company Profiles
      1. Pfizer Inc.
      2. Celltrion Healthcare
      3. Samsung Bioepis
      4. Amgen Inc.
      5. Mylan N.V.
      6. Sandoz (a Novartis division)
      7. Biocon
      8. Hospira (a Pfizer subsidiary)
      9. Merck & Co., Inc.
      10. Teva Pharmaceutical Industries Ltd.
  7. Analyst Views
  8. Future Outlook of the Market